As a new design strategy of anticancer drugs,antibody-drug conjugates have become a research hotspot in recent years. In 2013,the successful launch of ado trastuzumab emtansine(Kadcyla)provided a new solution for second-line treatment with trastuzumab-resistant HER2-positive advanced breast cancer patients. Based on its excellent clinical performance and HER2′s overex⁃pressing in many tumors,Roche further attempts to expand it for the therapy of HER2-positive metastatic breast cancer of each line and neoadjuvant for early breast cancer treatment,as well as applications to gastric cancer and non-small cell lung cancer(NSCLC) treatment. In general,results are mixed. Its position as second-line drugs of is further established,but factors such as tumor heteroge⁃neity are still a big challenge. This paper reviews the recent progress in these areas after its launch.%作为抗肿瘤药的全新设计策略，抗体药物偶联物是近年来广受关注的研究热点。2013年，阿多曲妥珠单抗依酯（ado trastuzumab emtansine，T-DM1，Kadcyla）成功上市，为耐曲妥珠单抗的HER2+晚期乳腺癌患者的二线治疗提供了全新的解决方案。基于该药优异的临床表现和HER2在多种肿瘤中的高表达，罗氏公司进一步尝试拓展其用于HER2+乳腺癌各线治疗和早期乳腺癌的新辅助治疗，以及胃癌和非小细胞肺癌的治疗。总体来说，结果有喜有忧，包括其二线用药地位进一步确立，但肿瘤异质性等因素仍带来极大挑战。本文综述了Kadcyla在机制及临床方面的研究进展。
展开▼
